Thyroid gland undifferentiated (anaplastic) carcinoma

Researchers are testing sacituzumab govitecan, an antibody-drug conjugate, in adults with advanced differentiated or anaplastic thyroid cancer that has stopped responding to radioactive iodine. The drug targets TROP-2, a protein found at high levels on these cancer cells. The tri…

This early-phase trial is testing whether giving a combination of two drugs (XL092 and cemiplimab) before surgery can help people with a rare and fast-growing thyroid cancer called anaplastic thyroid cancer. The study will enroll 12 participants to see if the treatment is safe an…

This phase 2 trial compares two radiation strategies for people with poorly differentiated or anaplastic thyroid cancer—rare and aggressive forms. One approach treats only the high-risk areas (selective coverage), while the other treats a larger region (comprehensive coverage). T…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This study tests a drug called FORE8394 (plixorafenib) in people aged 10 and older whose cancers have specific BRAF gene changes. The goal is to see if the drug can shrink tumors or slow their growth. About 254 participants with advanced solid tumors or brain tumors will take the…

This study tests whether two drugs, avutometinib and defactinib, can shrink or control certain types of advanced thyroid cancer that no longer respond to standard radioactive iodine treatment. The trial enrolls 30 adults with RAF dimer-driven differentiated or anaplastic thyroid …

This study tests two drugs, sacituzumab tirumotecan and tislelizumab, in people with advanced thyroid cancer that has stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or help people live longer. About 94 adults with three types of har…

This early-phase trial is testing whether combining two targeted drugs (dabrafenib and trametinib) with a precise form of radiation therapy (IMRT) is safe and can shrink tumors in people with a rare and aggressive thyroid cancer that has a specific BRAF mutation. Only 6 participa…

This early-phase study tests a new radioactive drug, [177Lu]Lu-AKIR001, in 15 adults with advanced solid tumors (like thyroid, head and neck, cervical, vulvar, or lung cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and sid…

This trial is testing two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific genetic change called BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing. About 3…

This phase II trial tests a combination of two drugs—MRG003 and pucotenlimab—in 60 people with a rare and aggressive form of thyroid cancer that cannot be removed by surgery. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the d…

This phase 2 trial is testing whether two drugs, pembrolizumab and lenvatinib, can shrink tumors and improve survival in 20 people with anaplastic thyroid cancer, a rare and fast-growing cancer. Participants will receive both drugs and be monitored for response and side effects. …

This study observes adults with advanced thyroid cancer who are receiving standard treatments in real-world settings, not in clinical trials. Researchers aim to understand barriers to accessing care and how well patients tolerate and respond to available medications. About 459 pa…